BridgeBio Pharma Posts $195M Q1 Revenue, Bernstein Raises Target to $114
BridgeBio Pharma reported Q1 revenues of $195 million, up from $117 million year-over-year and beating estimates by 8%, while reducing its loss to $0.84 per share. Bernstein raised its price target to $114 from $100 and BEYONTTRA™ secured approval in Brazil after U.S., E.U., and Japan.
1. Q1 Financial Results
BridgeBio Pharma delivered $195 million in Q1 2026 revenues, an increase from $117 million a year earlier and 8% above consensus. The company narrowed its quarterly loss to $0.84 per share, improving from a $0.88 loss in the same period of 2025.
2. Analyst Outlook
Investment firm Bernstein maintained an Outperform rating on the stock while boosting its price target from $100 to $114, reflecting confidence in BridgeBio’s ongoing revenue growth and pipeline momentum. This adjustment underscores bullish sentiment on the company’s ability to drive further commercial adoption.
3. BEYONTTRA Expansion
BEYONTTRA™ (acoramidis) received Brazilian approval based on data showing a 42% reduction in mortality and cardiovascular hospitalizations, building on existing approvals in the U.S., E.U., and Japan. This approval expands the drug’s addressable market and enhances BridgeBio’s global commercial prospects.